Source: Pharmacy Times articles
Patients with diabetes using glucagon-like peptide-1 (GLP-1) drugs face double the risk of developing neovascular age-related macular degeneration, highlighting crucial ocular health concerns.
Read More
by MM360 Staff | Jun 6, 2025 | Myeloma News | 0 comments
Source: Pharmacy Times articles
Patients with diabetes using glucagon-like peptide-1 (GLP-1) drugs face double the risk of developing neovascular age-related macular degeneration, highlighting crucial ocular health concerns.
Read More